NK MACS GMP Medium (Phenol Red) has been optimized for the cultivation, activation, and expansion of isolated human NK cells or NK cells from peripheral blood mononuclear cells (PBMCs). It is manufactured without animal-derived components. NK MACS GMP Medium (Phenol Red) is filled in flexible bags, making handling in GMP confirming processes easy.
Related products for NK MACS® GMP Medium (Phenol Red)
Expanded NK cells are fully functional and can be used in downstream assays, e.g. cytotoxicity assays. NK cells from PBMCs were expanded for 14 days in NK MACS Medium (research use) and NK MACS GMP Medium (Phenol Red) and were analyzed via flow cytometry for cytotoxicity against cell line K-562 at different effector-to-target (E:T) ratios.
NK MACS GMP Medium (Phenol Red) has been optimized for the cultivation, activation, and expansion of isolated human NK cells or NK cells from peripheral blood mononuclear cells (PBMCs). It is manufactured without animal-derived components. NK MACS GMP Medium (Phenol Red) is filled in flexible bags, making handling in GMP confirming processes easy.
NK MACS GMP Medium is serum- and xeno-component free.
- Flexible bags (2000 mL)
- Manufactured under strictly controlled conditions
- Consistent lot-to-lot performance
- Quality control: functionality test on every batch
NK MACS GMP Medium has beed developed for the cultivation and expansion of human NK cells from PBMCs or isolated human NK cells.
MACS GMP Products are manufactured and tested under a quality management system (ISO 13485) and are in compliance with relevant GMP guidelines. They are designed following the recommendations of USP <1043> on ancillary materials.
MACS GMP Products are for ex vivo cell processing only, and are not intended for human in vivo applications. For regulatory status in the USA, please contact your local representative.
Enter the lot number from your product label to access its Product Quality Certificated (PQC).
- Soldierer, M. et al. (2022) Genetic Engineering and Enrichment of Human NK Cells for CAR-Enhanced Immunotherapy of Hematological Malignancies, Front Immunol 13: doi: 10.3389/fimmu.2022.847008
- Fernandez, A. et al. (2021) Optimizing the Procedure to Manufacture Clinical-Grade NK Cells for Adoptive Immunotherapy Cancers (Basel) 13 (3): 577
- Oberschmidt, O. et al. (2019) Development of Automated Separation, Expansion, and Quality Control Protocols for Clinical-Scale Manufacturing of Primary Human NK Cells and Alpharetroviral Chimeric Antigen Receptor Engineering. Hum Gene Ther Methods 30 (3): 102-120
- de Jonge, P. et al. (2023) Good manufacturing practice production of CD34+ progenitor-derived NK cells for adoptive immunotherapy in acute myeloid leukemia Cancer Immunol. Immunother. 72 (10): 3323-3335
- Klöß, S. et al. (2017) Optimization of human NK cell manufacturing: Fully automated separation, improved ex vivo expansion using IL-21 with autologous feeder cells, and generation of Anti-CD123-CAR-expressing effector cells. Hum. Gene Ther. 28 (10): 897-913
- Motais, B. et al. (2021) Selection, Expansion, and Unique Pretreatment of Allogeneic Human Natural Killer Cells with Anti-CD38 Monoclonal Antibody for Efficient Multiple Myeloma Treatment Cells 10 (5): 967
You have previously chosen International as your location.
What do you want to do?